OncoMatch/Clinical Trials/NCT07817056
Risk-Stratified Management of Inavolisib-Induced Hyperglycemia and Patient Adherence
Official title: A Multicenter, Real-World Study Evaluating the Impact of Risk-Stratified Management of Inavolisib-Related Hyperglycemia on Patient Adherence
Is NCT07817056 recruiting? Yes, currently enrolling (Oct 2026).
Inavolisib is an effective targeted therapy for certain patients with breast cancer, but it may cause high blood sugar (hyperglycemia) as a side effect. This multicenter, real-world study aims to evaluate whether implementing a risk-stratified management strategy for inavolisib-related hyperglycemia can positively impact patients' adherence to their treatment. By categorizing patients based on their blood sugar risk levels and applying corresponding management plans, researchers hope to improve medication compliance and overall clinical outcomes in real-world clinical practice.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Biomarker criteria
Required: PIK3CA mutation
Diagnosed with PIK3CA-mutated, hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) locally advanced or metastatic breast cancer.
Required: ESR1 expression (positive)
hormone receptor-positive (HR+)
Required: HER2 (ERBB2) wild-type
HER2-negative
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07817056 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require PIK3CA?
Yes, PIK3CA mutation is a required biomarker for enrollment.
Does this trial require ESR1?
Yes, ESR1 expression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 wild-type is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages